Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis

Sepsis Clinical Trial

— EMPRESS  

Official title:

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (EMPRESS) Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06184659
• Other study ID #: RH-ITA-010
• Secondary ID: 2023-509703-33-0
• Status: Not yet recruiting
• Phase: Phase 4
• Start date: August 1, 2024
• Est. completion date: March 30, 2029

Study information

• Verified date: April 2024
• Source: Scandinavian Critical Care Trials Group
• Contact: Morten H Møller, MD, Professor, PhD
• Phone: 4535458685
• Email: morten.hylander.moeller[@]regionh.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The EMPRESS trial aims to test the two most commonly used antibiotics (meropenem and piperacillin/tazobactam) among intensive care patients with sepsis (blood poisoning), as the safety of these two drugs is unclear in this group of patients.

Description:

Background Piperacillin/tazobactam and meropenem are commonly used as empirical agents for patients with sepsis or septic shock. In a recent systematic review comparing empirical and/or definitive treatment with piperacillin/tazobactam versus meropenem for patients with severe bacterial infections, including sepsis and septic shock, it was shown that piperacillin/tazobactam may be associated with less favourable outcomes based on low or very low certainty of evidence. At present, it is unclear if piperacillin/tazobactam and meropenem are equally effective and safe for adults with sepsis. Objectives To assess the effects of empirical meropenem vs. piperacillin/tazobactam on mortality and other patient-important outcomes in critically ill adults with sepsis. Design Investigator-initiated, international, parallel-group, randomised, open-label, adaptive clinical trial with an integrated feasibility phase. The EMPRESS trial will employ adaptive stopping rules to increase the chance that the trial will be conclusive and response-adaptive randomisation to increase each participant's chance of being randomised to the superior intervention arm. Inclusion and exclusion criteria We will screen all adult patients who are critically ill with sepsis and who have indication for empirical treatment with meropenem or piperacillin/tazobactam. We will exclude patients with preceding intravenous treatment with meropenem or piperacillin/tazobactam for 24 hours or more; known pregnancy; known hypersensitivity or allergy to beta-lactam antibiotics; suspected or documented central nervous system infection; known infection or colonialisation with microorganism with acquired resistance to meropenem or piperacillin/tazobactam; current use of valproate; co-enrolment in other interventional trial where protocols collide; previous randomisation in EMPRESS; informed consent following inclusion expected to be unobtainable; and patients who are under coercive measures. Experimental intervention IV meropenem 1 g three times daily for up to 30 days. Control intervention IV piperacillin/tazobactam 4/0.5 g four times daily for up to 30 days. Outcomes The primary outcome is all-cause mortality at 30 days after randomisation. The secondary outcomes are the occurrence at least one serious adverse reaction (i.e., anaphylactic reaction to IV piperacillin/tazobactam or meropenem, invasive fungal infection, pseudomembranous colitis, or toxic epidermal necrolysis) within 30 days of randomisation; the occurrence of new isolation precautions due to resistant bacteria within 30 days of randomisation; days alive without life support (i.e., invasive mechanical ventilation, circulatory support, or renal replacement therapy) from randomisation to day 30 and 90; days alive and out of hospital from randomisation to day 30 and 90; all-cause mortality at day 90 and 180; and health-related quality of life at day 180 using EQ-5D-5L index values and EQ VAS. The feasibility outcomes are time to completion of feasibility phase (i.e., 200 participants randomised), recruitment proportion, proportion of participants without consent to the use of data, protocol adherence, and retention proportion. Statistics and stopping rules The trial will be analysed using Bayesian statistical methods with the primary analyses conducted in the intention-to-treat population. Outcomes will be analysed using logistic and linear regression models adjusted for relevant baseline characteristics and neutral and weakly informative to somewhat sceptical priors. Results will be presented as adjusted sample average treatment effects using both absolute (risk and mean differences) and relative (risk ratios and ratios of means) differences with 95% credible intervals and probabilities of benefit/harm. Adaptive analyses will start after follow-up and data collection concludes for 400 participants and every subsequent 300 participants up to a maximum of 14,000 participants. Adaptations will be based on data for the primary outcome. EMPRESS will use constant, symmetrical stopping rules for inferiority/superiority calibrated to keep the type 1 error rate at 5%. Further, the trial will be stopped for practical equivalence if there is 90% probability that the absolute risk difference between arms is less than 2.5%-points. Restricted response-adaptive randomisation will be used to ensure minimum allocation probabilities of 40% to both groups. Missing data will be imputed, and relevant secondary analyses, sensitivity analyses, and analyses of heterogeneity in treatment effects according to pre-defined baseline characteristics will be undertaken once the trial has been stopped. Trial design performance metrics Performance characteristics were evaluated assuming a 25% event probability for the primary outcome in the piperacillin/tazobactam arm and scenarios with no, small, and large differences corresponding to event probabilities of 25%, 22.5%, and 20% in the meropenem arm, respectively. The expected (mean) sample sizes under these scenarios are 5189, 5859, and 2570, respectively. The probabilities of conclusiveness (i.e., superiority or equivalence) are 99% in all scenarios, and the probabilities of superiority (power) are 72% and & 99% in the small and large difference scenarios, respectively. Estimated timeline - Primo 2024: authority approvals and first participant randomised - Primo 2025: feasibility phase analysis concluded - Medio 2028: expected inclusion of the last participant if trial continues to the expected sample size in the small-difference scenario (i.e., the largest expected sample size under the three different scenarios assessed) (section 19.9) - Medio 2032: expected inclusion of the last participant if the trial continues to the maximum sample size (n=14,000) (section 19.9) - Approximately 3 months after inclusion of the last participant: primary report on 30-day outcomes submitted - Approximately 6 months after inclusion of the last participant: report on 90-day outcomes submitted - Approximately 9 months after inclusion of the last participant: report on 180-day outcomes submitted

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 5800
• Est. completion date: March 30, 2029
• Est. primary completion date: June 30, 2028
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years
• Sepsis (including septic shock) defined according to the Sepsis-3 criteria (1), i.e., suspected or documented infection and an acute increase of = 2 points in the Sequential Organ Failure Assessment (SOFA) score (a marker of acute organ dysfunction)
• Critical illness defined as use of at least one of the following:

1. Invasive mechanical ventilation

2. Non-invasive ventilation

3. Continuous use of continuous positive airway pressure (CPAP) for hypoxia

4. Oxygen supplementation with an oxygen flow of = 10 litres (L)/minute independent of delivery system and total flows

5. Continuous infusion of any vasopressor or inotrope (excluding strictly procedure-related infusions)

• Clinical indication for empirical treatment with either meropenem or piperacillin/tazobactam

Exclusion Criteria:

• Preceding intravenous treatment with meropenem or piperacillin/tazobactam for > 24 hours prior to screening
• Fertile women < 60 years of age with known pregnancy or positive urine human gonadotropin (hCG) or plasma hCG
• Known hypersensitivity or allergy to beta-lactam antibiotics
• Suspected or documented central nervous system infection
• Known infection/colonialization with microorganism with acquired resistance against meropenem or piperacillin/tazobactam within the previous 3 months (e.g., ESBL-, AmpC- or carbapenemase-producing bacteria)
• Current or planned use of valproate within 30 days from randomisation
• Patient included in another interventional trial where co-enrolment with EMPRESS is not permitted
• Previously randomised into the EMPRESS trial
• Informed consent following inclusion expected to be unobtainable
• Patient under coercive measures

Related Conditions & MeSH terms

• Sepsis
• Septic Shock
• Shock, Septic
• Toxemia

Intervention

Drug:
• Meropenem
For meropenem, the standard dose is 1 g administered 3 times daily as a 30-minute intravenous (IV) infusion, and the high dose is 2 g administered 3 times daily by extended 3-hour infusion
• Piperacillin/Tazobactam
Standard dose of piperacillin/tazobactam 4/0.5 g administered 4 times daily as a 30-minute intravenous (IV) infusion or 3 times daily by extended 4-hour infusions and the recommended high dose is 4/0.5 g administered 4 times daily by extended 3-hour infusion

Locations

Country	Name	City	State
Denmark	Rigshospitalet	Copenhagen	København Ø

Sponsors (1)

Lead Sponsor	Collaborator
Scandinavian Critical Care Trials Group

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause mortality	Number of participant deaths from all causes at day 30 after randomisation.	Baseline to 30 days after enrollment
Secondary	Serious Adverse Reaction (SAR)	Number of participants with one or more serious adverse reactions (SARs, defined as anaphylactic shock to IV piperacillin/tazobactam or meropenem, invasive fungal infection, pseudomembranous colitis, or toxic epidermal necrolysis) within 30 days of randomisation.	Baseline to 30 days after enrollment
Secondary	Bacterial resistance	Number of participants with new isolation precautions due to one or more resistant bacteria within 30 days of randomisation.	Baseline to 30 days after enrollment
Secondary	Days alive without life support	Days alive without life support (i.e., invasive mechanical ventilation, circulatory support, or renal replacement therapy [including days in between intermittent renal replacement therapy]) from randomisation to day 30 and 90.	Baseline to day 30 and day 90 after enrollment
Secondary	Days alive and out of hospital	Days alive and out of hospital from randomisation to day 30 and 90.	Day 30 and day 90 after enrollment
Secondary	All-cause mortality	Number of participant deaths from any cause at day 90 and 180.	Day 90 and day 180 after enrollment
Secondary	Health-related Quality of Life (HRQoL)	HRQoL at day 180 using the 5-level EQ-5D version (EQ-5D-5L) index values (ranging from 0 to 100, where 0 represents the worst health you can imagine and 100 represents the best health you can imagine).	Day 180 after enrollment